

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 06/09/2004

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/624,659 07/21/2003 Pascal Druzgala ARYX-116XC1 7012 EXAMINER 23557 7590 06/09/2004 SALIWANCHIK LLOYD & SALIWANCHIK OWENS, AMELIA A A PROFESSIONAL ASSOCIATION ART UNIT PAPER NUMBER 2421 N.W. 41ST STREET SUITE A-1 1625 GAINESVILLE, FL 326066669

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary		Application No.		Applicant(s)		
			10/624,659	e	DRUZGALA ET AL.	
		Examiner		Art Unit		
			Amelia A. C		1625	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠ Responsive to communication(s) filed on <u>04 May 2004</u> .						
·	This action is FINAL . 2b)⊠ This action is non-final.					
, 	☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
· · · · · · · · · · · · · · · · · · ·	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
 4) Claim(s) 1-14 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 1,5 and 9 is/are rejected. 7) Claim(s) 2-4,6-8 and 10-14 is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. 						
Application Papers						
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some color None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
	on's Patent Drawing Review (Pre Statement(s) (PTO-1449 or			4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate	O-152)

Application/Control Number: 10/624,659

Art Unit: 1625

DETAILED ACTION

Claims 1-14 are pending. Drawings, 4 sheets, were filed with the application.

Response to Election/Restrictions

Applicant's election without traverse of species of Group II, pyridine in Paper No. dated May 4, 2004 is acknowledged. *The claims have been examined to the extent they read on the elected invention.*

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Information Disclosure Statement

The information disclosure statement (IDS) was submitted on December 29, 2003.

Accordingly, the examiner has considered the information disclosure statement.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1, 5 and 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fey et al USP 5,849,749.

Application/Control Number: 10/624,659

Art Unit: 1625

Fey et al teach 6-(hydroxymethyl-ethyl)pyridines as inhibitors of HMG-CoA reductase.

See column 1 lines 13-36. The sole difference is that the reference does not recite the specified characteristics.

One of ordinary skill in the art would be motivated to practice the claimed invention as a chemical compound and its properties are inseparable. Patentability does not therefore depend solely on the similarity of the formula of the claimed compound to that of a prior art compound. The unobviousness of its properties must also be considered. As the reference compounds are inhibitors of HMG-CoA reductase, they would inherently possess the claimed properties absent some showing to the contrary.

Claims 2-4, 6-8, 10-14 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

The claims have been examined to the extent they read on the elected invention.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amelia A. Owens whose telephone number is 571-272-0690. The examiner can normally be reached on Monday - Friday from 8:30 - 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/624,659

Art Unit: 1625

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Amelia A. Owens Primary Examiner

Art Unit 1625